[Dopaminergic and noradrenergic therapy of cognitive impairment].
The paper presents recent clinical data on usage of pronoran, a dopaminergic and noradrenergic medication, in the treatment of mild and moderate cognitive impairment in elderly. Efficacy of pronoran was shown in a number of placebo-controlled as well as open clinical trials including those carried out in Russia. Presented are also the results of the large-scale study PROMETEY which has been performed in Russia in 2004-2005. The study revealed that 70% of elderly neurological patients had cognitive impairment. Pronoran was included in the treatment of cognitive impairment in the frames of this study and showed a marked therapeutic effect in 82% cases.
Zakharov
V V
VV
D000368:Aged; D000369:Aged, 80 and over; D003072:Cognition Disorders / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000378:metabolism*; D010891:Piribedil / Q000627:therapeutic use*
D018491:Dopamine Agonists; D010891:Piribedil; D009638:Norepinephrine